Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

WCLC 2024

New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy...

Dr Li Zhang - Sun Yat-Sen University Cancer Centre, Guangzhou, China

New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients ( Dr Li Zhang - Sun Yat-Sen University Cancer Centre, Guangzhou, China )

Tusamitamab ravtansine versus docetaxel in previously treated advanced...

Prof Benjamin Besse - Gustave Roussy, Paris, France

Tusamitamab ravtansine versus docetaxel in previously treated advanced nonsquamous NSCLC: Results from phase 3 CARMEN-LC03 trial ( Prof Benjamin Besse - Gustave Roussy, Paris, France )

Cemiplimab monotherapy could be a new treatment option for first line advanced...

Dr Ana Baramidze - Todua Clinic, Tbilisi, Georgia

Cemiplimab monotherapy could be a new treatment option for first line advanced NSCLC patients ( Dr Ana Baramidze - Todua Clinic, Tbilisi, Georgia )

Amivantamab-lazertinib continue to show benefit as a first-line standard-of...

Dr Marina Garassino - University of Chicago, Chicago, USA

Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

TROP2 expression measured by QCS is a promising predictor of clinical outcomes...

Dr Marina Garassino - University of Chicago, Chicago, USA

TROP2 expression measured by QCS is a promising predictor of clinical outcomes in patients with mNSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

More from ecancer